Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930902 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase 1 study of Resectable Pancreatic Carcinoma and Stage II Pancreatic Cancer AJCC v6 and v7, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02930902 is a Phase 1 study of Resectable Pancreatic Carcinoma and Stage II Pancreatic Cancer AJCC v6 and v7 that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02930902, a Phase 1 study of Resectable Pancreatic Carcinoma and Stage II Pancreatic Cancer AJCC v6 and v7, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and paricalcitol with or without chemotherapy before surgery may help to control the disease.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Nab-paclitaxel
- DRUG Paricalcitol
- DRUG Gemcitabine Hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930902
The ClinicalTrials.gov registry entry for NCT02930902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Resectable Pancreatic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02930902 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02930902 about?
NCT02930902 is a clinical study titled "Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery". This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help carry tumor-killing substances ...
What is the current status of trial NCT02930902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-02-20. Estimated completion is 2023-01-03.
What conditions does trial NCT02930902 study?
This clinical trial studies the following conditions: Resectable Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7.
What interventions are being tested in trial NCT02930902?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Nab-paclitaxel (DRUG), Paricalcitol (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02930902?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02930902 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Pancreatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
RECRUITING · Phase 2
-
Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Resectable Pancreatic Carcinoma
All registered trials for this condition
Stage II Pancreatic Cancer AJCC v6 and v7
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.